Explore
Upload

DocSlides is a free service to upload presentations and documents.

Upload Now

Search Results for 'Rbv Weeks'

Rbv Weeks published presentations and documents on DocSlides.

MK3 MK3 + RBV

MK3 MK3 + RBV

  • min-jolicoeur
  • 10 Slides

Randomisation. Open-label. W8. * Liver biopsy or ...

SOF + EBR + GZR + RBV

SOF + EBR + GZR + RBV

  • test
  • 4 Slides

N = 12. N = 13. W24. W16. SOF + EBR + GZR + RBV. ...

SOF + RBV

SOF + RBV

  • debby-jeon
  • 7 Slides

SOF + RBV. Randomisation*. 1 : 1 : 1. Open-label....

PEG alfa-2a RBV versus

PEG alfa-2a RBV versus

  • alexa-scheidler
  • 0 Slides

. PEG alfa-. 2a . versus. INF RBV . APRICOT S...

Daclatasvir + Sofosbuvir + RBV in GT3

Daclatasvir + Sofosbuvir + RBV in GT3

  • sophia2
  • 9 Slides

. with Advanced Liver Disease. ALLY-3+ Study. Phas...

C-WORTHY Study Part D: grazoprevir + elbasvir + RBV in genotype 3

C-WORTHY Study Part D: grazoprevir + elbasvir + RBV in genotype 3

  • UnicornLove
  • 7 Slides

C-WORTHY/D. GZR + EBR + RBV. GZR + EBR + RBV. N =...

Open-label

Open-label

  • pamella-moone
  • 4 Slides

* Liver biopsy or . Fibroscan. ≤. 12.5 . kPa....

C-WORTHY/B

C-WORTHY/B

  • stefany-barnette
  • 8 Slides

Randomisation*. Open-label. >. 18 years. HCV ...

Chronic hepatitis C: guidelines for screening and

Chronic hepatitis C: guidelines for screening and

  • aaron
  • 0 Slides

treatment. Lisa M. Glass, MD. Clinical Lecturer. ...

Hepatitis C Imtiaz Alam, M.D.

Hepatitis C Imtiaz Alam, M.D.

  • olivia-moreira
  • 0 Slides

Medical Director, Austin Hepatitis Center. 1. Hep...

M.W. Fried , 1 M. Buti,

M.W. Fried , 1 M. Buti,

  • iamamercy
  • 18 Slides

2. G.J. Dore,. 3. P. Ferenci,. 4. . I. Jacobson...

Design

Design

  • test
  • 8 Slides

PTV150/r + OBV + . DSV . + RBV. PTV150/r + . DSV...

Out With the Old and In With the New, Again?

Out With the Old and In With the New, Again?

  • test
  • 37 Slides

Out With the Old, In With the New. Current Standa...

HIV and HCV Update for the Pharmacist – June 2014

HIV and HCV Update for the Pharmacist – June 2014

  • marina-yarberry
  • 60 Slides

John J. . Faragon. , . PharmD. , BCPS, AAHIV-P. R...

GZR + EBR

GZR + EBR

  • celsa-spraggs
  • 5 Slides

C-WORTHY Study Part C: . grazoprevir. . + . elba...

Hepatitis C Drug Pipeline

Hepatitis C Drug Pipeline

  • cheryl-pisano
  • 36 Slides

HCV WORLD CAB .  FEBRUARY 2014. BANGKOK, THAI...

Randomisation

Randomisation

  • pamella-moone
  • 10 Slides

*. 1:1. Open-label. ≥ 18 years. HCV genotype ...

SOF/VEL

SOF/VEL

  • trish-goza
  • 6 Slides

400/100 mg . qd. N = 120. N = 120. W12. SOF + RBV...

David Fletcher, MD

David Fletcher, MD

  • tatiana-dople
  • 24 Slides

Department of Medicine. University of Toronto. Co...

C-WORTHY Study Part

C-WORTHY Study Part

  • karlyn-bohler
  • 12 Slides

D : . grazoprevir. . + . elbasvir. + RBV in ge...

Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care

Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care

  • lois-ondreau
  • 0 Slides

Sameh W. Boktor, MD, MPH. Medical Epidemiologist....

Updated Guidelines for Managing HIV/HCV Co-Infection

Updated Guidelines for Managing HIV/HCV Co-Infection

  • karlyn-bohler
  • 0 Slides

John J . Faragon. , . PharmD. , BCPS, AAHIV-P. Re...

Prevention strategies for HIV/HCV co infection

Prevention strategies for HIV/HCV co infection

  • giovanna-bartolotta
  • 0 Slides

Isabelle Andrieux-Meyer, MD. Médecins Sans Front...

Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care

Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care

  • webraph
  • 50 Slides

Sameh W. Boktor, MD, MPH. Medical Epidemiologist. ...

NS5A and polymerase inhibitors

NS5A and polymerase inhibitors

  • LoveBug
  • 16 Slides

Mark Sulkowski, MD. Professor of Medicine. Johns H...

How to optimize treatment of G1 patients?

How to optimize treatment of G1 patients?

  • KissesForYou
  • 12 Slides

Prof. G. K. K. Lau 2012. Standard of care (SOC) ...

WEEKS ENDING LOG 2014-2015

WEEKS ENDING LOG 2014-2015

  • giovanna-bartolotta
  • 1 Slides

Weeks Weeks Ending Ending Saturday Saturday Weeks...

Reddy KR. Lancet Infect Dis. 2015;15:27-35

Reddy KR. Lancet Infect Dis. 2015;15:27-35

  • natalia-silvester
  • 6 Slides

ATTAIN. SMV + TVR placebo. + PEG-IFN + RBV. TVR ...

State of the Art Therapy for HCV

State of the Art Therapy for HCV

  • liane-varnes
  • 56 Slides

Last Updated: February . 21, 2014. Robert G. Gish...

Future HCV Treatment Paradigms

Future HCV Treatment Paradigms

  • kittie-lecroy
  • 48 Slides

Mark Sulkowski, MD . Professor of Medicine. Medic...

Edited by

Edited by

  • celsa-spraggs
  • 137 Slides

Morris Sherman MD . BCh. PhD FRCP(C) . Associate...

3 D (Paritaprevir

3 D (Paritaprevir

  • myesha-ticknor
  • 13 Slides

-Ritonavir. -Ombitasvir . + Dasabuvir) . + RBV in...

C-SCAPE

C-SCAPE

  • pasty-toler
  • 14 Slides

Design. C-SCAPE . Study. : . grazoprevir. ± . e...

SIRIUS

SIRIUS

  • tawny-fly
  • 10 Slides

Placebo. LDV/SOF + placebo. Randomisation*. 1 : 1...

Current strategies for the management of treatment naïve a

Current strategies for the management of treatment naïve a

  • min-jolicoeur
  • 60 Slides

Mark S. Sulkowski, MD. Medical Director, Viral He...

TURQUOISE-I

TURQUOISE-I

  • natalia-silvester
  • 5 Slides

OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + ...

Dore G. J

Dore G. J

  • pasty-toler
  • 10 Slides

Hepatol. 2016; 64:19-28. MALACHITE. TVR + PEG-IF...

Direct Acting Antivirals: What are they? What is their pl

Direct Acting Antivirals: What are they? What is their pl

  • tawny-fly
  • 28 Slides

Mark Sulkowski, MD. Associate Professor of Medici...

Étude PEARL III : ABT-450/r/267 + ABT-333 ± RBV

Étude PEARL III : ABT-450/r/267 + ABT-333 ± RBV

  • tatiana-dople
  • 4 Slides

dans les génotypes 1b naïfs de traitement . (1)...

3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in

3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in

  • yoshiko-marsland
  • 14 Slides

TURQUOISE-II. Phase 3. . Treatment. Naïve and ...

Copyright © 2024 DocSlides. All Rights Reserved